Abstract
The epidemiology of invasive meningococcal disease continues to change rapidly, even in the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease caused by serogroup C has been achieved in countries that have implemented meningococcal C or quadrivalent meningococcal ACWY conjugate vaccines. Initiation of mass immunization programs with meningococcal A conjugate vaccines across the meningitis belt of Africa may lead to the interruption of cyclical meningococcal epidemics. A meningococcal B vaccination program in New Zealand has led to a decreased incidence of high rates of endemic serogroup B disease. Increases in serogroup Y disease have been observed in certain Nordic countries which, if they persist, may require consideration of use of a multiple serogroup vaccine. The imminent availability of recombinant broadly protective serogroup B vaccines may provide the tools for further control of invasive meningococcal disease in areas where serogroup B disease predominates. Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required.
Original language | English |
---|---|
Pages (from-to) | B26-B36 |
Journal | Vaccine |
Volume | 30 |
Issue number | SUPPL. 2 |
DOIs | |
Publication status | Published - 30 Apr 2012 |
Bibliographical note
Funding Information:The authors have received grant and contract funding from Novartis Vaccines, sponsor of the Meningococcus Scientific Exchange Meeting, but have no financial interest in the company.
Keywords
- Epidemiology
- Meningococcus
- Neisseria meningitidis
- Surveillance